Subscribe To
MCK / Bankrupt Rite Aid resolves drug supply dispute with McKesson
MCK News
By Zacks Investment Research
November 2, 2023
McKesson (MCK) Beats on Q2 Earnings, Raises '23 EPS View
McKesson's (MCK) second-quarter fiscal 2024 results benefit from growth in the United States. Divestment hurts the International segment. more_horizontal
By Zacks Investment Research
November 1, 2023
Here's What Key Metrics Tell Us About McKesson (MCK) Q2 Earnings
While the top- and bottom-line numbers for McKesson (MCK) give a sense of how the business performed in the quarter ended September 2023, it could be more_horizontal
By Seeking Alpha
November 1, 2023
McKesson Corporation (MCK) Q2 2024 Earnings Call Transcript
McKesson Corporation (NYSE:MCK ) Q2 2024 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Rachel Rodriguez - Vice President o more_horizontal
By Reuters
November 1, 2023
McKesson lifts annual profit forecast after strong quarterly results
Drug distributor McKesson Corp on Wednesday raised its annual profit forecast, banking on strong demand for specialty medicines. more_horizontal
By Zacks Investment Research
October 30, 2023
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank. more_horizontal
By Zacks Investment Research
October 25, 2023
Are Investors Undervaluing McKesson (MCK) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Neverthe more_horizontal
By Reuters
October 17, 2023
Bankrupt Rite Aid resolves drug supply dispute with McKesson
Pharmacy chain Rite Aid has settled a critical dispute with drug supplier McKesson Corp to ensure that customers' prescriptions will continue to be fi more_horizontal
By Zacks Investment Research
October 12, 2023
McKesson (MCK) Upgraded to Strong Buy: Here's What You Should Know
McKesson (MCK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). more_horizontal